Hologic's Q3FY12 prelims promise to please investors, while $3.7bn Gen-Probe buy makes tracks
This article was originally published in Clinica
Executive Summary
Investors in Hologic should not have to worry about receiving bad news from the women's health company this earnings season after the company confirmed that its fiscal third quarter profits will meet, or even exceed, the guidance it had set in April.